Targeting the Alternatively Spliced Soluble Isoform of CTLA-4: Prospects for Immunotherapy?

References

• June CH, Jackson KM, Ledbetter JA, Leiden JM, Lindsten T, Thompson CB. Two distinct mechanisms of interleukin-2 gene expression in human T lymphocytes J. Autoimmun. 2 Suppl., 55–65 (1989).
   PubMed Web of Science ®Google Scholar
• Ledbetter JA, Imboden JB, Schieven GL et al. CD28 ligation in T-cell activation: evidence for two signal transduction pathways. Blood 75(7), 1531–1539(1990).
   PubMed Web of Science ®Google Scholar
• Linsley PS, Clark EA, Ledbetter JA. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc. Natl. Acad. Sci. USA 87(13), 5031–5035(1990).
   PubMed Web of Science ®Google Scholar
• Riley JL, June CH. The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. Blood 105(1), 13–21(2005).
   PubMed Web of Science ®Google Scholar
• Brunet JF, Denizot F, Luciani MF et al. A new member of the immunoglobulin superfamily – CTLA-4. Nature 328(6127), 267–270(1987).
   PubMed Web of Science ®Google Scholar
• Linsley PS, Wallace PM, Johnson J et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 257(5071), 792–795(1992).
   PubMed Web of Science ®Google Scholar
• Lenschow DJ, Zeng Y, Thistlethwaite JR et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science 257(5071), 789–792(1992).
   PubMed Web of Science ®Google Scholar
• Harper K, Balzano C, Rouvier E, Mattei MG, Luciani MF, Golstein P. CTLA-4 and CD28 activated lymphocyte molecules are closely related in both mouse and human as to sequence, message expression, gene structure, and chromosomal location. J. Immunol. 147(3), 1037–1044(1991).
   PubMed Web of Science ®Google Scholar
• Freeman GJ, Borriello F, Hodes RJ et al. Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice. Science 262(5135), 907–909(1993).
   PubMed Web of Science ®Google Scholar
• Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3(5), 541–547 (1995).
   PubMed Web of Science ®Google Scholar
• Waterhouse P, Penninger JM, Timms E et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 270(5238), 985–988 (1995).
   PubMed Web of Science ®Google Scholar
• Tivol EA, Boyd SD, McKeon S et al. CTLA4Ig prevents lymphoproliferation and fatal multiorgan tissue destruction in CTLA-4-deficient mice. J. Immunol. 158(11), 5091–5094(1997).
   PubMed Web of Science ®Google Scholar
• Tivol EA, Gorski J. Re-establishing peripheral tolerance in the absence of CTLA-4: complementation by wild-type T cells points to an indirect role for CTLA-4. J. Immunol. 169(4), 1852–1858(2002).
   PubMed Web of Science ®Google Scholar
• Takahashi T, Tagami T, Yamazaki S et al. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192(2), 303–310(2000).
   PubMed Web of Science ®Google Scholar
• Read S, Malmstrom V, Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J. Exp. Med. 192(2), 295–302(2000).
   PubMed Web of Science ®Google Scholar
• Manzotti CN, Tipping H, Perry LC et al. Inhibition of human T cell proliferation by CTLA-4 utilizes CD80 and requires CD25+ regulatory T cells. Eur. J. Immunol. 32(10), 2888–2896(2002).
   PubMed Web of Science ®Google Scholar
• Wing K, Onishi Y, Prieto-Martin P et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 322(5899), 271–275(2008).
   PubMed Web of Science ®Google Scholar
• Peggs KS, Quezada SA, Chambers CA, Korman AJ, Allison JP. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J. Exp. Med. 206(8), 1717–1725(2009).
   PubMed Web of Science ®Google Scholar
• Corse E, Allison JP. Cutting edge: CTLA-4 on effector T cells inhibits in trans. J. Immunol. 189(3), 1123–1127(2012).
   PubMed Web of Science ®Google Scholar
• Walker LS, Sansom DM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses. Nat. Rev. Immunol. 11(12), 852–863(2011).
   PubMed Web of Science ®Google Scholar
• Grohmann U, Orabona C, Fallarino F et al. CTLA-4-ig regulates tryptophan catabolism in vivo. Nat. Immunol. 3(11), 1097–1101 (2002).
   PubMed Web of Science ®Google Scholar
• Dejean AS, Beisner DR, Ch’en IL et al. Transcription factor Foxo3 controls the magnitude of T cell immune responses by modulating the function of dendritic cells. Nat. Immunol. 10(5), 504–513(2009).
   PubMed Web of Science ®Google Scholar
• Qureshi OS, Zheng Y, Nakamura K et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332(6029), 600–603(2011).
   PubMed Web of Science ®Google Scholar
• Schneider H, Downey J, Smith A et al. Reversal of the TCR stop signal by CTLA-4. Science 313(5795), 1972–1975(2006).
   PubMed Web of Science ®Google Scholar
• Lu Y, Schneider H, Rudd CE. Murine regulatory T cells differ from conventional T cells in resisting the CTLA-4 reversal of TCR stop-signal. Blood 120(23), 4560–4570(2012).
   PubMed Web of Science ®Google Scholar
• Verhagen J, Gabrysova L, Minaee S et al. Enhanced selection of FoxP3+ T-regulatory cells protects CTLA-4-deficient mice from CNS autoimmune disease. Proc. Natl. Acad. Sci. USA 106(9), 3306–3311(2009).
   PubMed Web of Science ®Google Scholar
• Verhagen J, Genolet R, Britton GJ et al. CTLA-4 controls the thymic development of both conventional and regulatory T cells through modulation of the TCR repertoire. Proc. Natl. Acad. Sci. USA 110(3), E221–E230 (2013).
   PubMed Web of Science ®Google Scholar
• Nishikawa K, Linsley PS, Collins AB, Stamenkovic I, McCluskey RT, Andres G. Effect of CTLA-4 chimeric protein on rat autoimmune anti-glomerular basement membrane glomerulonephritis. Eur. J. Immunol. 24(6), 1249–1254(1994).
   PubMed Web of Science ®Google Scholar
• Blazar BR, Taylor PA, Linsley PS, Vallera DA. In vivo blockade of CD28/CTLA4: B7/BB1 interaction with CTLA4-ig reduces lethal murine graft-versus-host disease across the major histocompatibility complex barrier in mice. Blood 83(12), 3815–3825(1994).
   PubMed Web of Science ®Google Scholar
• Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 265(5176), 1225–1227(1994).
   PubMed Web of Science ®Google Scholar
• Knoerzer DB, Karr RW, Schwartz BD, Mengle-Gaw LJ. Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-ig. J. Clin. Invest. 96(2), 987–993(1995).
   PubMed Web of Science ®Google Scholar
• Webb LM, Walmsley MJ, Feldmann M. Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. Eur. J. Immunol. 26(10), 2320–2328(1996).
   PubMed Web of Science ®Google Scholar
• Abrams JR, Lebwohl MG, Guzzo CA et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J. Clin. Invest. 103(9), 1243–1252(1999).
   PubMed Web of Science ®Google Scholar
• Moreland LW, Alten R, Van den Bosch F et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. Arthritis Rheum. 46(6), 1470–1479(2002).
   PubMed Web of Science ®Google Scholar
• Kremer JM, Westhovens R, Leon M et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N. Engl. J. Med. 349(20), 1907–1915(2003).
   PubMed Web of Science ®Google Scholar
• Ruperto N, Lovell DJ, Quartier P et al. Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 372(9636), 383–391(2008).
   PubMed Web of Science ®Google Scholar
• Kremer JM, Dougados M, Emery P et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a Phase IIb, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 52(8), 2263–2271(2005).
   PubMed Web of Science ®Google Scholar
• Kremer JM, Genant HK, Moreland LW et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum. 58(4), 953–963(2008).
   PubMed Web of Science ®Google Scholar
• Bluestone JA, St Clair EW, Turka LA. CTLA4Ig: bridging the basic immunology with clinical application. Immunity 24(3), 233–238(2006).
   PubMed Web of Science ®Google Scholar
• Wofsy D, Hillson JL, Diamond B. Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions. Arthritis Rheum. 64(11), 3660–3665(2012).
   PubMed Web of Science ®Google Scholar
• Larsen CP, Pearson TC, Adams AB et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-ig with potent immunosuppressive. properties Am. J. Transplant. 5(3), 443–453(2005).
   PubMed Web of Science ®Google Scholar
• Vincenti F, Larsen C, Durrbach A et al. Costimulation blockade with belatacept in renal transplantation. N. Engl. J. Med. 353(8), 770–781(2005).
   PubMed Web of Science ®Google Scholar
• Vincenti F, Blancho G, Durrbach A et al. Five-year safety and efficacy of belatacept in renal transplantation. J. Am. Soc. Nephrol. 21(9), 1587–1596(2010).
   PubMed Web of Science ®Google Scholar
• Vincenti F, Larsen CP, Alberu J et al. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am. J. Transplant. 12(1), 210–217(2012).
   PubMed Web of Science ®Google Scholar
• Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 182(2), 459–465(1995).
   PubMed Web of Science ®Google Scholar
• Kearney ER, Walunas TL, Karr RW et al. Antigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. J. Immunol. 155(3), 1032–1036(1995).
   PubMed Web of Science ®Google Scholar
• Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks CD28-dependent T cell activation. J. Exp. Med. 183(6), 2541–2550(1996).
   PubMed Web of Science ®Google Scholar
• Sullivan RJ, Atkins MB. Cytokine therapy in melanoma. J. Cutan. Pathol. 37(Suppl. 1), 60–67 (2010).
   PubMedGoogle Scholar
• Couzin-Frankel J. Breakthrough of the year 2013. cancer immunotherapy. Science 342(6165), 1432–1433(2013).
   PubMed Web of Science ®Google Scholar
• Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271(5256), 1734–1736(1996).
   PubMed Web of Science ®Google Scholar
• Chambers CA, Kuhns MS, Allison JP. Cytotoxic T lymphocyte antigen-4 (CTLA-4) regulates primary and secondary peptide-specific CD4(+) T cell responses. Proc. Natl. Acad. Sci. USA 96(15), 8603–8608(1999).
   PubMed Web of Science ®Google Scholar
• van Elsas A, Hurwitz AA, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190(3), 355–366(1999).
   PubMed Web of Science ®Google Scholar
• van Elsas A, Sutmuller RP, Hurwitz AA et al. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J. Exp. Med. 194(4), 481–489(2001).
   PubMed Web of Science ®Google Scholar
• Camacho LH, Antonia S, Sosman J et al. Phase I/II trial of tremelimumab in patients with metastatic melanoma. J. Clin. Oncol. 27(7), 1075–1081(2009).
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Lorigan P, Hersey P et al. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clin. Cancer Res. 16(3), 1042–1048(2010).
   PubMed Web of Science ®Google Scholar
• Ribas A, Kefford R, Marshall MA et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J. Clin. Oncol. 31(5), 616–622(2013).
   PubMed Web of Science ®Google Scholar
• Calabro L, Morra A, Fonsatti E et al. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, Phase 2 trial. Lancet Oncol. 14(11), 1104–1111(2013).
   PubMed Web of Science ®Google Scholar
• Sangro B, Gomez-Martin C, de la Mata M et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J. Hepatol. 59(1), 81–88(2013).
   PubMed Web of Science ®Google Scholar
• Lens M, Testori A, Ferucci PF. Ipilimumab targeting CD28-CTLA-4 axis: new hope in the treatment of melanoma. Curr. Top. Med. Chem. 12(1), 61–66(2012).
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363(8), 711–723(2010).
   PubMed Web of Science ®Google Scholar
• Wolchok JD, Weber JS, Maio M et al. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in Phase II clinical trials. Ann. Oncol. 24(8), 2174–2180(2013).
   PubMed Web of Science ®Google Scholar
• Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J. Exp. Med. 210(7), 1389–1402(2013).
   PubMed Web of Science ®Google Scholar
• Marabelle A, Kohrt H, Sagiv-Barfi I et al. Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J. Clin. Invest. 123(6), 2447–2463(2013).
   PubMed Web of Science ®Google Scholar
• Williams EL, Dunn SN, James S et al. Immunomodulatory monoclonal antibodies combined with peptide vaccination provide potent immunotherapy in an aggressive murine neuroblastoma model. Clin. Cancer Res. 19(13), 3545–3555(2013).
   PubMed Web of Science ®Google Scholar
• Jensen BA, Pedersen SR, Christensen JP, Thomsen AR. The availability of a functional tumor targeting T-cell repertoire determines the anti-tumor efficiency of combination therapy with anti-CTLA-4 and anti-4-1BB antibodies. PLoS ONE 8(6), e66081(2013).
   PubMed Web of Science ®Google Scholar
• Agarwalla P, Barnard Z, Fecci P, Dranoff G, Curry WT Jr. Sequential immunotherapy by vaccination with GM-CSF-expressing glioma cells and CTLA-4 blockade effectively treats established murine intracranial tumors. J. Immunother. 35(5), 385–389(2012).
   PubMed Web of Science ®Google Scholar
• Iannone R, Miele L, Maiolino P, Pinto A, Morello S. Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model. Am. J. Cancer Res. 4(2), 172–181(2014).
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Butterfield LH, Shuai Y, Gooding WE, Kalinski P, Kirkwood JM. Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-alpha or TLR-9 agonist and GM-CSF with peptide vaccination. J. Immunother. 35(9), 702–710(2012).
   PubMed Web of Science ®Google Scholar
• Yu P, Steel JC, Zhang M et al. Simultaneous inhibition of two regulatory T-cell subsets enhanced interleukin-15 efficacy in a prostate tumor model. Proc. Natl. Acad. Sci. USA 109(16), 6187–6192(2012).
   PubMed Web of Science ®Google Scholar
• Page DB, Postow MA, Callahan MK, Wolchok JD. Checkpoint modulation in melanoma: an update on ipilimumab and future directions. Curr. Oncol. Rep. 15(5), 500–508(2013).
   PubMed Web of Science ®Google Scholar
• Simpson TR, Li F, Montalvo-Ortiz W et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J. Exp. Med. 210(9), 1695–1710(2013).
   PubMed Web of Science ®Google Scholar
• Schmidt EM, Wang CJ, Ryan GA et al. Ctla-4 controls regulatory T cell peripheral homeostasis and is required for suppression of pancreatic islet autoimmunity. J. Immunol. 182(1), 274–282(2009).
   PubMed Web of Science ®Google Scholar
• Laurent S, Queirolo P, Boero S et al. The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-alpha production. J. Transl. Med. 11 108–5876 – 5811–5108(2013).
   PubMed Web of Science ®Google Scholar
• Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD, Caturegli P. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Sci. Transl. Med. 6, 230–245(2014).
   Web of Science ®Google Scholar
• Lu Y, Schneider H, Rudd CE. Murine regulatory T cells differ from conventional T cells in resisting the CTLA-4 reversal of TCR stop-signal. Blood 120(23), 4560–4570(2012).
   PubMed Web of Science ®Google Scholar
• Rigby MR, Trexler AM, Pearson TC, Larsen CP. CD28/CD154 blockade prevents autoimmune diabetes by inducing nondeletional tolerance after effector T-cell inhibition and regulatory T-cell expansion. Diabetes 57(10), 2672–2683(2008).
   PubMed Web of Science ®Google Scholar
• Pruitt SK, Boczkowski D, de Rosa N et al. Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells. Eur. J. Immunol. 41(12), 3553–3563(2011).
   PubMed Web of Science ®Google Scholar
• Wu L, Yun Z, Tagawa T, Rey-McIntyre K, de Perrot M. CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma. Mol. Cancer. Ther. 11(8), 1809–1819(2012).
   PubMed Web of Science ®Google Scholar
• Magistrelli G, Jeannin P, Herbault N et al. A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur. J. Immunol. 29(11), 3596–3602(1999).
   PubMed Web of Science ®Google Scholar
• Oaks MK, Hallett KM, Penwell RT, Stauber EC, Warren SJ, Tector AJ. A native soluble form of CTLA-4. Cell. Immunol. 201(2), 144–153(2000).
   PubMed Web of Science ®Google Scholar
• Oaks MK, Hallett KM. Cutting edge: a soluble form of CTLA-4 in patients with autoimmune thyroid disease. J. Immunol. 164(10), 5015–5018(2000).
   PubMed Web of Science ®Google Scholar
• Vijayakrishnan L, Slavik JM, Illes Z et al. An autoimmune disease-associated CTLA-4 splice variant lacking the B7 binding domain signals negatively in T cells. Immunity 20(5), 563–575(2004).
   PubMed Web of Science ®Google Scholar
• Teft WA, Kirchhof MG, Madrenas J. A molecular perspective of CTLA-4 function. Annu. Rev. Immunol. 24, 65–97 (2006).
   PubMed Web of Science ®Google Scholar
• Mayans S, Lackovic K, Nyholm C et al. CT60 genotype does not affect CTLA-4 isoform expression despite association to T1D and AITD in northern Sweden. BMC Med. Genet. 8, 3 (2007).
   PubMed Web of Science ®Google Scholar
• Saverino D, Brizzolara R, Simone R et al. Soluble CTLA-4 in autoimmune thyroid diseases: relationship with clinical status and possible role in the immune response dysregulation. Clin. Immunol. 123(2), 190–198(2007).
   PubMed Web of Science ®Google Scholar
• Cao J, Zou L, Luo P, Chen P, Zhang L. Increased production of circulating soluble co-stimulatory molecules CTLA-4, CD28 and CD80 in patients with rheumatoid arthritis Int. Immunopharmacol. 14(4), 585–592(2012).
   PubMed Web of Science ®Google Scholar
• Ip WK, Wong CK, Leung TF, Lam CW. Elevation of plasma soluble T cell costimulatory molecules CTLA-4, CD28 and CD80 in children with allergic asthma. Int. Arch. Allergy Immunol. 137(1), 45–52(2005).
   PubMed Web of Science ®Google Scholar
• Ip WK, Wong CK, Leung TF, Lam CW. Plasma concentrations of soluble CTLA-4, CD28, CD80 and CD86 costimulatory molecules reflect disease severity of acute asthma in children. Pediatr. Pulmonol. 41(7), 674–682(2006).
   PubMed Web of Science ®Google Scholar
• Wong CK, Lit LC, Tam LS, Li EK, Lam CW. Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus. Rheumatology (Oxford) 44(8), 989–994(2005).
   PubMed Web of Science ®Google Scholar
• Sato S, Fujimoto M, Hasegawa M et al. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis. Rheumatology (Oxford) 43(10), 1261–1266(2004).
   PubMed Web of Science ®Google Scholar
• Wang XB, Kakoulidou M, Giscombe R et al. Abnormal expression of CTLA-4 by T cells from patients with myasthenia gravis: effect of an AT-rich gene sequence. J. Neuroimmunol. 130(1–2), 224–232(2002).
   PubMed Web of Science ®Google Scholar
• Toussirot E, Saas P, Deschamps M et al. Increased production of soluble CTLA-4 in patients with spondylarthropathies correlates with disease activity. Arthritis Res. Ther. 11(4), R101(2009).
   PubMed Web of Science ®Google Scholar
• Simone R, Tenca C, Fais F et al. A soluble form of CTLA-4 is present in paediatric patients with acute lymphoblastic leukaemia and correlates with CD1d+ expression. PLoS ONE 7(9), e44654(2012).
   PubMed Web of Science ®Google Scholar
• Ueda H, Howson JM, Esposito L et al. Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423(6939), 506–511(2003).
   PubMed Web of Science ®Google Scholar
• Purohit S, Podolsky R, Collins C et al. Lack of correlation between the levels of soluble cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) and the CT-60 genotypes. J. Autoimmune Dis. 2, 8 (2005).
   PubMedGoogle Scholar
• Berry A, Tector M, Oaks MK. Lack of association between sCTLA-4 levels in human plasma and common CTLA-4 polymorphisms. J. Negat. Results Biomed. 7 8–5751 – 5757–5758(2008).
   PubMedGoogle Scholar
• Ward FJ, Dahal LN, Wijesekera SK et al. The soluble isoform of CTLA-4 as a regulator of T-cell responses. Eur. J. Immunol. 43(5), 1274–1285(2013).
   PubMed Web of Science ®Google Scholar
• Dahal LN, Hall LS, Barker RN, Ward FJ. Indoleamine 2,3 dioxygenase contributes to transferable tolerance in rat red blood cell inducible model of experimental autoimmune haemolytic anaemia. Clin. Exp. Immunol. 173(1), 58–66(2013).
   PubMed Web of Science ®Google Scholar
• Collins AV, Brodie DW, Gilbert RJ et al. The interaction properties of costimulatory molecules revisited. Immunity 17(2), 201–210(2002).
   PubMed Web of Science ®Google Scholar
• Davis SJ, Ikemizu S, Evans EJ, Fugger L, Bakker TR, van der Merwe PA. The nature of molecular recognition by T cells. Nat. Immunol. 4(3), 217–224(2003).
   PubMed Web of Science ®Google Scholar